|
|
See Category: Factors influencing health status and contact with health services
ICD-10 (CM) Code and Descriptor
|
Z12.4 |
Encounter for screening for malignant neoplasm of cervix
This code is considered unacceptable as a principal diagnosis.
|
Z124 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 42.01%
|
21.51%
|
10.85%
|
6.69%
|
4.94%
|
3.51%
|
2.66%
|
2.15%
|
1.68%
|
1.22%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for Z12.4*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
87624
|
HPV HI-RISK TYP POOLED RSLT |
34,875
|
34,879
|
|
G0145
|
SCR C/V CYTO,THINLAYER,RESCR |
26,218
|
26,218
|
|
G0123
|
SCREEN CERV/VAG THIN LAYER |
16,955
|
16,955
|
|
88175
|
CYTOPATH C/V AUTO FLUID REDO |
13,121
|
13,125
|
|
88142
|
CYTOPATH C/V THIN LAYER |
8,550
|
8,552
|
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
5,750
|
5,763
|
|
Q0091
|
OBTAINING SCREEN PAP SMEAR |
5,207
|
5,207
|
|
G0467
|
FQHC VISIT, ESTAB PT |
4,876
|
4,879
|
|
G0101
|
CA SCREEN;PELVIC/BREAST EXAM |
3,958
|
3,960
|
|
99213
|
OFFICE O/P EST LOW 20 MIN |
3,243
|
3,243
|
|
87491
|
CHLMYD TRACH DNA AMP PROBE |
3,012
|
3,026
|
|
87591
|
N.GONORRHOEAE DNA AMP PROB |
2,990
|
3,004
|
|
G0476
|
HPV COMBO ASSAY CA SCREEN |
2,985
|
2,985
|
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
1,833
|
1,838
|
|
99214
|
OFFICE O/P EST MOD 30 MIN |
1,704
|
1,704
|
|
80061
|
LIPID PANEL |
1,558
|
1,558
|
|
80053
|
COMPREHEN METABOLIC PANEL |
1,531
|
1,531
|
|
87625
|
HPV TYPES 16 & 18 ONLY |
1,379
|
1,381
|
|
84443
|
ASSAY THYROID STIM HORMONE |
1,245
|
1,247
|
|
88305
|
TISSUE EXAM BY PATHOLOGIST |
1,086
|
1,221
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
Z12.4 related to the following DRG Codes:
951
|
